ITOS ITeos Therapeutics Inc
460
$17.01
$0.43
(2.47%)
| Watchers | 460 |
| 52-Wk Low | $8.20 |
| 52-Wk High | $18.75 |
| Market Cap | $627.24M |
| Volume | 166,647.00 |
| 52-Wk High | $18.75 |
| 52-Wk Low | $8.20 |
iTeos Therapeutics presents preclinical data on EOS-984The Fly • about 1 month ago
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Share to Feed
WATERTOWN, Mass. and GOSSELIES, Belgium, April 07, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and...
This is a signal that ITOS's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...
iTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) saw a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 2,010,000 shares, an...
This is a signal that ITOS's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...
This indicator may be signaling that ITOS's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
This is a signal that ITOS's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...
Trexquant Investment LP grew its position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS Free Report) by 10.8% during the 3rd quarter, according to the company in its most recent filing...
Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on iTeos Therapeutics (ITOS Research Report), Viracta Therapeutics...